Europe Becomes ‘Epicentre’ For COVID-19 As Spain Declares State Of Emergency & US Cases Rise 26/10/2020 Madeleine Hoecklin & James Hacker Spain announced a state of emergency on Sunday and ordered a nationwide curfew just days after becoming the first Western European country to surpass one million confirmed cases. The curfew and restrictions on gatherings of more than six people has made Spain the latest country in Europe to toughen its guidelines, after France placed 46 […] Continue reading -> The Pandemic Will End – But Tuberculosis, Tobacco and Air Pollution Will Continue To Steal Our Global Breath – Unless We Reimagine The Future 20/10/2020 Svĕt Lustig Vijay The COVID-19 pandemic will end at some point. But TB, tobacco use, air pollution and other lung diseases will continue to “steal the breath and life of millions of people every year”, unless we reimagine the future, said WHO’s director-general Dr Tedros Adhanon Ghebreyesus, appearing at the opening of the 51st Union World Conference On […] Continue reading -> Much-Touted Remdesivir Fails To Reduce COVID-19 Deaths; Results Of WHO-Coordinated Solidarity Trial 16/10/2020 Elaine Ruth Fletcher & Madeleine Hoecklin Two more experimental COVID-19 drugs, including the much-touted Remdesivir, appear to have fallen by the wayside, failing to show significant reductions in mortality among seriously ill patients. Interim results on Remdesivir and three other drug treatments being studied as part of the WHO Solidarity Therapeutics Trial, the world’s largest randomized controlled trial of COVID-19 drugs, […] Continue reading -> The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means? 14/10/2020 Ellen t'Hoen A sweeping proposal by India and South Africa to suspend the protection of intellectual property (IP) related to COVID-19 health products is set to come before the The World Trade Organization’s TRIPS Council this week. The closed door discussion lays the groundwork for what could prove to be the most significant public debate over […] Continue reading -> Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Pandemic Will End – But Tuberculosis, Tobacco and Air Pollution Will Continue To Steal Our Global Breath – Unless We Reimagine The Future 20/10/2020 Svĕt Lustig Vijay The COVID-19 pandemic will end at some point. But TB, tobacco use, air pollution and other lung diseases will continue to “steal the breath and life of millions of people every year”, unless we reimagine the future, said WHO’s director-general Dr Tedros Adhanon Ghebreyesus, appearing at the opening of the 51st Union World Conference On […] Continue reading -> Much-Touted Remdesivir Fails To Reduce COVID-19 Deaths; Results Of WHO-Coordinated Solidarity Trial 16/10/2020 Elaine Ruth Fletcher & Madeleine Hoecklin Two more experimental COVID-19 drugs, including the much-touted Remdesivir, appear to have fallen by the wayside, failing to show significant reductions in mortality among seriously ill patients. Interim results on Remdesivir and three other drug treatments being studied as part of the WHO Solidarity Therapeutics Trial, the world’s largest randomized controlled trial of COVID-19 drugs, […] Continue reading -> The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means? 14/10/2020 Ellen t'Hoen A sweeping proposal by India and South Africa to suspend the protection of intellectual property (IP) related to COVID-19 health products is set to come before the The World Trade Organization’s TRIPS Council this week. The closed door discussion lays the groundwork for what could prove to be the most significant public debate over […] Continue reading -> Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Much-Touted Remdesivir Fails To Reduce COVID-19 Deaths; Results Of WHO-Coordinated Solidarity Trial 16/10/2020 Elaine Ruth Fletcher & Madeleine Hoecklin Two more experimental COVID-19 drugs, including the much-touted Remdesivir, appear to have fallen by the wayside, failing to show significant reductions in mortality among seriously ill patients. Interim results on Remdesivir and three other drug treatments being studied as part of the WHO Solidarity Therapeutics Trial, the world’s largest randomized controlled trial of COVID-19 drugs, […] Continue reading -> The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means? 14/10/2020 Ellen t'Hoen A sweeping proposal by India and South Africa to suspend the protection of intellectual property (IP) related to COVID-19 health products is set to come before the The World Trade Organization’s TRIPS Council this week. The closed door discussion lays the groundwork for what could prove to be the most significant public debate over […] Continue reading -> Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means? 14/10/2020 Ellen t'Hoen A sweeping proposal by India and South Africa to suspend the protection of intellectual property (IP) related to COVID-19 health products is set to come before the The World Trade Organization’s TRIPS Council this week. The closed door discussion lays the groundwork for what could prove to be the most significant public debate over […] Continue reading -> Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> Posts navigation Older posts